Reply to 'Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease'

Azita H Talasaz^{1

2

3}, Behnood Bikdeli^{4

5

6}

Affiliations

¹ Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY, USA.
² Department of Pharmacy, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, USA.
³ Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, VA, USA.
⁴ Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. behnood.bikdeli@yale.edu.
⁵ Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. behnood.bikdeli@yale.edu.
⁶ Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, CT, USA. behnood.bikdeli@yale.edu.

Comment

Azita H Talasaz et al. Nat Rev Cardiol. 2024 Aug.

. 2024 Aug;21(8):594-595.

doi: 10.1038/s41569-024-01029-7.

Azita H Talasaz^{1

2

3}, Behnood Bikdeli^{4

5

6}

¹ Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY, USA.
² Department of Pharmacy, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, USA.
³ Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, VA, USA.
⁴ Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. behnood.bikdeli@yale.edu.
⁵ Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. behnood.bikdeli@yale.edu.
⁶ Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, CT, USA. behnood.bikdeli@yale.edu.

No abstract available

Comment on

Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.
Talasaz AH, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom JW, Siegal DM, Monreal M, Jimenez D, Vaduganathan M, Castellucci LA, Cuker A, Barnes GD, Connors JM, Secemsky EA, Van Tassell BW, De Caterina R, Kurlander JE, Aminian A, Piazza G, Goldhaber SZ, Moores L, Middeldorp S, Kirtane AJ, Elkind MSV, Angiolillo DJ, Konstantinides S, Lip GYH, Stone GW, Cushman M, Krumholz HM, Mehran R, Bhatt DL, Bikdeli B. Talasaz AH, et al. Nat Rev Cardiol. 2024 Aug;21(8):574-592. doi: 10.1038/s41569-024-01003-3. Epub 2024 Mar 20. Nat Rev Cardiol. 2024. PMID: 38509244 Review.
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease.
Wärme J, Sundqvist MO, James S, Hofmann R. Wärme J, et al. Nat Rev Cardiol. 2024 Aug;21(8):593. doi: 10.1038/s41569-024-01028-8. Nat Rev Cardiol. 2024. PMID: 38698181 No abstract available.

1. Wärme, J., Sundqvist, M. O., James, S. & Hofmann, R. Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01028-8 (2024).
1. Talasaz, A. H. et al. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01003-3 (2024).
1. Venerito, M. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment. Pharmacol. Ther. 47, 1464–1471 (2018). - DOI - PubMed
1. Sarri, G. L., Grigg, S. E. & Yeomans, N. D. Helicobacter pylori and low-dose aspirin ulcer risk: a meta-analysis. J. Gastroenterol. Hepatol. 34, 517–525 (2019). - DOI - PubMed
1. Ng, J. C. & Yeomans, N. D. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. Med. J. Aust. 209, 306–311 (2018). - DOI - PubMed